保险公司强制用药使用障碍与保险满意度下降及不良临床结局相关:炎症性肠病 Partners 调查
保险障碍与保险满意度下降相关,且预先授权与皮质类固醇补救(OR 2.24)、被迫换药与持续疾病活动(OR 3.28)、拒药与IBD相关手术(OR 8.92)相关。
要点
- 72%患者经历保险公司强制用药障碍,最常见为预先授权(51%)。
- 拒药、预先授权延迟、治疗缺口和高自付额保险与保险满意度负相关。
- 预先授权与皮质类固醇补救、被迫换药与持续疾病活动、拒药与IBD相关手术相关。
核心结论
- 保险公司强制用药障碍在IBD患者中频繁发生,并与保险满意度下降及不良下游临床结局相关。
研究设计与样本
- 在IBD Partners纵向队列中开展调查,评估用药使用障碍的频率及患者报告影响。
主要发现
- 72%经历保险公司强制障碍,最常见为预先授权(51%);15%被保险公司拒绝IBD药物,22%经历保险相关治疗缺口,8%被保险公司强制从有效药物换药。
- 保险满意度(1-7 Likert量表)与拒药、预先授权相关延迟、治疗缺口和高自付额健康保险计划覆盖呈负相关。
- 初次调查后一年内,预先授权与皮质类固醇补救相关(OR 2.24,95%CI 1.25-4.00),被迫换药与持续疾病活动相关(OR 3.28,95%CI 1.56-6.89),拒药与IBD相关手术相关(OR 8.92,95%CI 1.97-40.39)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Insurer-mandated barriers to timely initiation of advanced therapies used to treat inflammatory bowel disease (IBD) have been shown to worsen clinical outcomes and increase healthcare utilization, yet rarely alter the medication ultimately prescribed. METHODS: We conducted a survey within the IBD Partners longitudinal cohort to evaluate the frequency and patient-reported impacts of medication utilization barriers on insurance satisfaction and clinical outcomes. Barriers included medication denials, prior authorizations, and forced medication switches. Variables associated with insurance satisfaction, measured on a 1-7 Likert scale, were identified. The association between insurance-related barriers and downstream clinical outcomes (surgery, corticosteroid requirement, and disease activity) were evaluated. RESULTS: Two thousand seventeen patients (age 45 [interquartile range 34-58] years, 73% female) were included. Seventy-two percent experienced an insurer-mandated barrier, most commonly prior authorizations (51%). Fifteen percent were denied an IBD medication by their insurer, 22% experienced an insurance-related gap in therapy, and 8% were forced by their insurer to switch from an effective medication. Insurance satisfaction was negatively associated with medication denials, prior authorization-related delays, gaps in therapy, and high-deductible health plan coverage. In the year following the initial survey, several insurance barriers were linked to negative downstream clinical outcomes, including prior authorizations associated with corticosteroid rescue (odds ratio [OR] 2.24, 95% confidence interval [CI] 1.25-4.00), forced medication switches associated with continued disease activity (OR 3.28, 95% CI 1.56-6.89), and medication denials associated with IBD-related surgery (OR 8.92, 95% CI 1.97-40.39). DISCUSSION: These data illustrate the frequency and negative impacts of insurer-mandated medication barriers on patients with IBD, including decreased insurance satisfaction and negative downstream clinical outcomes.
引用
- Constant BD, Long MD, Scott FI, et al. Insurer-Mandated Medication Utilization Barriers are Associated With Decreased Insurance Satisfaction and Adverse Clinical Outcomes: An Inflammatory Bowel Disease Partners Survey. Am J Gastroenterol. 2024. PMID: 38819004. doi:10.14309/ajg.0000000000002851
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。